Skip to the beginning of the images gallery

Add to Wish List

Sintilimab Biosimilar - Research Grade

Name: Sintilimab Biosimilar - Research Grade
SKU: ICH5001
Price: 315 USD
Availability: InStock

In stock

Only %1 left

SKU

ICH5001

Add to Compare

Be the first to review this product

$315.00 - $19,890.00

Sintilimab Biosimilar - Research Grade

Endotoxin

<1EU/mg Determined by LAL gel clotting assay

Purity

>95% by SDS-PAGE and HPLC

Species Reactivity

Human

Target

PD-1

Concentration

>1mg/ml

Isotype

Human IgG4

Host

Humanized

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q15116

Shipping Conditions

Blue ice

Background

This is a research-grade biosimilar of sintilimab, supplied as an unconjugated, non-therapeutic recombinant analog of the originator anti-PD-1 antibody rather than the clinical drug itself. It is a fully human IgG4 monoclonal built around the programmed cell death protein 1 (PD-1) target and is intended strictly for research use only (RUO); it is not for human or veterinary use. The molecule is useful in the laboratory as a well-characterised PD-1-binding reagent for a range of applications, including target-engagement and binding studies, blockade/neutralisation assays that interrupt the PD-1/PD-L1 axis, isotype-matched positive controls in checkpoint-inhibitor screening, benchmarking of novel candidate antibodies, and as a building block for ADC or engineering workflows. It is offered at research-grade low endotoxin (<1 EU/mg), with an ultra-low endotoxin option (<0.5 EU/mg) suitable for sensitive in-vitro and preclinical standard-setting work, and is available in bulk milligram-to-gram quantities to support scale-up and assay development. Because it is produced for research rather than dosing patients, it functions as a cost-effective, consistent reference reagent for PD-1-focused programmes. PD-1 (programmed cell death protein 1; gene PDCD1, UniProt Q15116) is an inhibitory immune-checkpoint receptor of the CD28/immunoglobulin superfamily, expressed on activated T cells and, more broadly, on B cells, NK cells, and some myeloid populations. Its cytoplasmic tail carries ITIM and ITSM motifs that, upon ligand engagement, recruit the phosphatase SHP-2 to dampen TCR and CD28 signalling, reducing proliferation, cytokine production, and effector function. PD-1 has two ligands, PD-L1 (CD274) and PD-L2 (PDCD1LG2). Under normal physiology this axis maintains peripheral tolerance and limits immunopathology, but tumours and chronically infected tissues exploit it to drive T-cell exhaustion and immune evasion. Blocking PD-1 or its ligands releases this brake and restores anti-tumour T-cell activity, the mechanistic rationale behind checkpoint-inhibitor drugs such as sintilimab.

Other Names

Programmed cell death protein 1, Pdcd1, CD279

Specificity

Detects human PD-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Sintilimab.

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Formulation

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Storage

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Write Your Own Review

You're reviewing:Sintilimab Biosimilar - Research Grade

Your Rating

Rating